![Logo](/assets/logo-d3f1fdf60522f0983e71f9fcc720cb7da5b55c0b748ed5bded3d2fbf81387bf0.png)
PMC:7499532
Annnotations
LitCovid-PD-FMA-UBERON
Id | Subject | Object | Predicate | Lexical cue | fma_id |
---|---|---|---|---|---|
T1 | 187-189 | Body_part | denotes | AG | http://purl.org/sig/ont/fma/fma61898 |
T2 | 387-389 | Body_part | denotes | AG | http://purl.org/sig/ont/fma/fma61898 |
LitCovid-PD-MONDO
Id | Subject | Object | Predicate | Lexical cue | mondo_id |
---|---|---|---|---|---|
T1 | 105-113 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T2 | 320-328 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
T3 | 331-340 | Disease | denotes | infection | http://purl.obolibrary.org/obo/MONDO_0005550 |
T4 | 345-353 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T5 | 507-515 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T6 | 545-553 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
T7 | 889-897 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
T8 | 960-968 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T9 | 1059-1067 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
LitCovid-PD-CLO
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T1 | 13-14 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T2 | 66-67 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T3 | 268-269 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T4 | 505-506 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T5 | 638-639 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T6 | 806-811 | http://purl.obolibrary.org/obo/NCBITaxon_10239 | denotes | virus |
T7 | 958-959 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | A |
T8 | 1012-1017 | http://purl.obolibrary.org/obo/NCBITaxon_10239 | denotes | virus |
T9 | 1096-1097 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | A |
LitCovid-PubTator
Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
---|---|---|---|---|---|
1 | 105-113 | Disease | denotes | COVID-19 | MESH:C000657245 |
9 | 545-555 | Species | denotes | SARS-CoV-2 | Tax:2697049 |
10 | 889-899 | Species | denotes | SARS-CoV-2 | Tax:2697049 |
11 | 1059-1069 | Species | denotes | SARS-CoV-2 | Tax:2697049 |
12 | 320-340 | Disease | denotes | SARS-CoV-2 infection | MESH:C000657245 |
13 | 345-353 | Disease | denotes | COVID-19 | MESH:C000657245 |
14 | 507-515 | Disease | denotes | COVID-19 | MESH:C000657245 |
15 | 960-968 | Disease | denotes | COVID-19 | MESH:C000657245 |
LitCovid-sentences
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T1 | 0-135 | Sentence | denotes | Viewpoint of a WHO Advisory Group Tasked to Consider Establishing a Closely-Monitored Challenge Model of COVID-19 in Healthy Volunteers |
T2 | 137-145 | Sentence | denotes | Abstract |
T3 | 146-154 | Sentence | denotes | Abstract |
T4 | 155-382 | Sentence | denotes | WHO convened an Advisory Group (AG) to consider the feasibility, potential value and limitations of establishing a closely-monitored challenge model of experimental SARS-CoV-2 infection and COVID-19 in healthy adult volunteers. |
T5 | 383-462 | Sentence | denotes | The AG included experts in design, establishment and performance of challenges. |
T6 | 463-957 | Sentence | denotes | This report summarizes issues that render a COVID-19 model daunting to establish (SARS-CoV-2’s potential to cause severe/fatal illness, its high transmissibility, and lack of a “rescue treatment” to prevent progression from mild/moderate to severe clinical illness) and it proffers prudent strategies for stepwise model development, challenge virus selection, guidelines for manufacturing challenge doses, and ways to contain SARS-CoV-2 and prevent transmission to household/community contacts. |
T7 | 958-1095 | Sentence | denotes | A COVID-19 model could demonstrate protection against virus shedding and/or illness induced by prior SARS-CoV-2 challenge or vaccination. |
T8 | 1096-1275 | Sentence | denotes | A limitation of the model is that vaccine efficacy in experimentally challenged healthy young adults cannot per se be extrapolated to predict efficacy in elderly/high-risk adults. |